Selenium supplementation suppresses tumor necrosis factor alpha-induced human immunodeficiency virus type 1 replication in vitro.

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Selenium supplementation suppresses tumor necrosis factor alpha-induced human immunodeficiency virus type 1 replication in vitro.

AIDS Res Hum Retroviruses. 1997 Oct 10;13(15):1325-32. Unique Identifier : AIDSLINE MED/97479768
Hori K; Hatfield D; Maldarelli F; Lee BJ; Clouse KA; Division of Cytokine Biology, Center for Biologics Evaluation and; Research, Food and Drug Administration, Rockville, Maryland; 20852, USA.

Abstract: Selenium is a nutritionally essential trace element that is important for optimal function of the immune system. It is incorporated into selenoproteins as the amino acid selenocysteine and it is known to inhibit the expression of some viruses. In this study, we show that selenium supplementation for 3 days prior to exposure to tumor necrosis factor alpha (TNF-alpha) partially suppresses the induction of human immunodeficiency virus type 1 (HIV-1) replication in both chronically infected T lymphocytic and monocytic cell lines. In acute HIV-1 infection of T lymphocytes and monocytes in the absence of exogenous TNF-alpha, the suppressive effect of selenium supplementation was not observed. However, selenium supplementation did suppress the enhancing effect of TNF-alpha on HIV-1 replication in vitro in acutely infected human monocytes, but not in T lymphocytes. Selenium supplementation also increased the activities of the selenoproteins, glutathione peroxidase (GPx) and thioredoxin reductase (TR), which serve as cellular antioxidants. Taken together, these results suggest that selenium supplementation may prove beneficial as an adjuvant therapy for AIDS through reinforcement of endogenous antioxidative systems.

Keywords: Cells, Cultured Glutathione Peroxidase/METABOLISM Human HIV Infections/IMMUNOLOGY/*METABOLISM/VIROLOGY HIV Seronegativity HIV-1/*GROWTH & DEVELOPMENT HIV-1 Reverse Transcriptase/METABOLISM Monocytes/VIROLOGY Proteins/METABOLISM Selenium/*PHARMACOLOGY T-Lymphocytes/VIROLOGY Thioredoxin Reductase (NADPH)/METABOLISM Tumor Necrosis Factor/*PHARMACOLOGY Virus Replication/*DRUG EFFECTS JOURNAL ARTICLE
980228
M9820721

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .